Pharma Stock Cuts Earnings Outlook: Still a Buying Opportunity

Merck & Co. Inc. NYSE: MRK delivered a solid earnings report before the market opened on July 30, 2024. However, the stock was down over 4% in early trading after the company cut its full-year earnings forecast. The pullback comes as MRK stock is up 17% in 2024. If you look beyond the headline numbers, this could be a good buy-the-dip opportunity. MRK Merck & Co., Inc. Today Merck & Co., Inc. $115.88 -11.90 (-9.31$99.14 ▼ $134.63 Dividend Yield 2.66$135.36 Ad ...